S100A8 and S100A9 are calcium-binding proteins of the S100 family, primarily expressed in neutrophils and monocytes. They exist as a stable heterodimer and play critical roles in inflammation by modulating leukocyte recruitment, cytokine secretion, and inflammatory responses. S100A8/A9 serves as a potential biomarker for diagnosing and monitoring inflammation-associated diseases and as a therapeutic target. Infection-induced inflammation leads to increased S100A8/A9 expression, which contributes to inflammatory responses and tissue damage. In metabolic inflammation, such as gout, diabetes, and obesity, S100A8/A9 is secreted in disease-specific patterns and is associated with disease progression. In immune-related inflammation, S100A8/A9 is upregulated in autoimmune diseases and hypersensitivity reactions, playing a role in leukocyte migration and cytokine production. In degenerative diseases, S100A8/A9 is involved in age-related inflammation and disease progression. S100A8/A9 has intracellular and extracellular functions, including cytoskeleton modulation, arachidonic acid metabolism, and antimicrobial activity. It also exhibits anti-inflammatory properties under certain conditions. S100A8/A9 is a key player in inflammation, with potential as a therapeutic target for inflammation-associated diseases. Its role in cytokine secretion, leukocyte recruitment, and immune modulation makes it a promising biomarker and therapeutic target. S100A8/A9 is involved in various inflammatory processes, including infection, autoimmune diseases, and metabolic disorders. It is a potential target for treatment in inflammation-associated diseases, with inhibitors and antibodies showing promise in reducing inflammation and tissue damage. S100A8/A9 is a significant biomarker in inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. Its levels are associated with disease activity and prognosis. S100A8/A9 is a potential therapeutic target for inflammation-associated diseases, with inhibitors and antibodies showing promise in reducing inflammation and tissue damage.S100A8 and S100A9 are calcium-binding proteins of the S100 family, primarily expressed in neutrophils and monocytes. They exist as a stable heterodimer and play critical roles in inflammation by modulating leukocyte recruitment, cytokine secretion, and inflammatory responses. S100A8/A9 serves as a potential biomarker for diagnosing and monitoring inflammation-associated diseases and as a therapeutic target. Infection-induced inflammation leads to increased S100A8/A9 expression, which contributes to inflammatory responses and tissue damage. In metabolic inflammation, such as gout, diabetes, and obesity, S100A8/A9 is secreted in disease-specific patterns and is associated with disease progression. In immune-related inflammation, S100A8/A9 is upregulated in autoimmune diseases and hypersensitivity reactions, playing a role in leukocyte migration and cytokine production. In degenerative diseases, S100A8/A9 is involved in age-related inflammation and disease progression. S100A8/A9 has intracellular and extracellular functions, including cytoskeleton modulation, arachidonic acid metabolism, and antimicrobial activity. It also exhibits anti-inflammatory properties under certain conditions. S100A8/A9 is a key player in inflammation, with potential as a therapeutic target for inflammation-associated diseases. Its role in cytokine secretion, leukocyte recruitment, and immune modulation makes it a promising biomarker and therapeutic target. S100A8/A9 is involved in various inflammatory processes, including infection, autoimmune diseases, and metabolic disorders. It is a potential target for treatment in inflammation-associated diseases, with inhibitors and antibodies showing promise in reducing inflammation and tissue damage. S100A8/A9 is a significant biomarker in inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. Its levels are associated with disease activity and prognosis. S100A8/A9 is a potential therapeutic target for inflammation-associated diseases, with inhibitors and antibodies showing promise in reducing inflammation and tissue damage.